Aktis Oncology, Inc. AKTS
Set alert
15.93 USD -0.92 -5.46%
At close · Oct 30
15.93 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
15.77 Day range 17.03
15.06 52-week range 32.23
- YTD
- -28.88%
- 1 year
- -28.88%
- Open
- 17.03
- Prev close
- 16.85
- Mkt cap
- 886.02M
- Vol
- 251.54K
- Avg vol
- 361.91K
- EPS
- -1.70
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 15.77
- High
- 17.03
- Forward P/E
- -8.45
- Beta
- 0.00
- Short ratio
- 10.89
- Inst. own
- 73.01%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 12, 2026
- 50-d avg
- 22.96
- 200-d avg
- 21.42
- 1y target
- 35.39
2Y chart
Events in this range
- Mar 30, 2026Earnings: -18.19; estimate -21.59333; surprise 15.76%
- May 11, 2026Earnings: -0.38; estimate -0.31; surprise -22.58%
- Jun 16, 2026Rating: Raymond James · — → Strong Buy
- Jul 14, 2026Rating: JP Morgan · Overweight → Overweight
- Aug 13, 2026Earnings: -0.44; estimate -0.43065; surprise -2.17%
- Aug 19, 2026Rating: BMO Capital · — → Outperform
- Aug 19, 2026Rating: Wedbush · — → Outperform
- Sep 9, 2026Rating: Oppenheimer · — → Outperform
- Oct 2, 2026Rating: Wedbush · Outperform → Outperform
Signals (33)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 21, 2026 | 1 week ago |
| RSI: Oversold | Sep 30, 2026 | 1 month ago |
| RSI: Oversold | Sep 23, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 9, 2026 | 1 month ago |
| SMA: Bearish | Sep 8, 2026 | 1 month ago |
| SMA: Bullish | Aug 24, 2026 | 2 months ago |
| SMA: Bearish | Aug 20, 2026 | 2 months ago |
| SMA: Bullish | Aug 18, 2026 | 2 months ago |
| SMA: Bearish | Aug 17, 2026 | 2 months ago |
| SMA: Bullish | Aug 14, 2026 | 2 months ago |
| SMA: Bearish | Aug 12, 2026 | 2 months ago |
| SMA: Bullish | Aug 11, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 10, 2026 | 2 months ago |
| SMA: Bearish | Jul 28, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 8, 2026 | 3 months ago |
| RSI: Overbought | Jun 23, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 12, 2026 | 4 months ago |
| SMA: Bullish | Jun 11, 2026 | 4 months ago |
| SMA: Bearish | Jun 5, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 4, 2026 | 5 months ago |
| MACD: Buy Signal | May 22, 2026 | 5 months ago |
| SMA: Bullish | May 20, 2026 | 5 months ago |
| SMA: Bearish | May 18, 2026 | 5 months ago |
| SMA: Bullish | May 12, 2026 | 5 months ago |
| SMA: Bearish | May 8, 2026 | 5 months ago |
| SMA: Bullish | May 1, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 30, 2026 | 6 months ago |
| SMA: Bearish | Apr 28, 2026 | 6 months ago |
| SMA: Bullish | Apr 16, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 9, 2026 | 6 months ago |
| MACD: Sell Signal | Mar 18, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 16, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 12, 2026 | 7 months ago |
Key statistics
- Market cap
- 1.01B
- Enterprise value
- 495.07M
- Trailing P/E
- 0.00
- Forward P/E
- -8.45
- PEG ratio
- 0.00
- Price / sales
- 100.35
- Price / book
- 2.07
- EPS (TTM)
- -1.70
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 10.06M
- Revenue growth
- 111.40%
- Free cash flow
- 0
- Total cash
- 517.32M
- Total debt
- 11.24M
- Return on equity
- 0.00%
- Shares outstanding
- 53.75M
- Short % of float
- 20.12%
- 50-day average
- 22.96
- 200-day average
- 21.42
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 35.39 +122.2% upside
Now 15.93
- Target (low)
- 31.50
- Target (mean)
- 35.39
- Target (high)
- 40.00
Ratings (0m) 10 10 buy · 0 hold · 0 sell
- Strong buy1
- Buy9
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 12, 2026
Expected Nov 12, 2026. Consensus EPS estimate -0.45803.
Financials — quick view
AKTS Revenue — quarterly 3.38M
AKTS Net income — quarterly -24.14M
AKTS EPS — quarterly -0.44
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2026 | Sep 30, 2026 | -0.47 | — | — | — |
| Aug 13, 2026 | Jun 30, 2026 | -0.43065 | -0.44 | -0.01 | -2.17% |
| May 11, 2026 | Mar 31, 2026 | -0.31 | -0.38 | -0.07 | -22.58% |
| Mar 30, 2026 | Dec 31, 2025 | -21.59 | -18.19 | +3.40 | +15.76% |
| Dec 3, 2025 | Sep 30, 2025 | -0.11 | -1.39 | -1.28 | -1,163.64% |
| Nov 14, 2024 | Sep 30, 2024 | -0.10 | -0.04 | +0.06 | +60.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 2, 2026 | Wedbush | reit | Outperform | Outperform |
| Sep 9, 2026 | Oppenheimer | init | — | Outperform |
| Aug 19, 2026 | Wedbush | init | — | Outperform |
| Aug 19, 2026 | BMO Capital | init | — | Outperform |
| Jul 14, 2026 | JP Morgan | main | Overweight | Overweight |
| Jun 16, 2026 | Raymond James | init | — | Strong Buy |
About Aktis Oncology, Inc.
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- aktisoncology.com
News
- Aktis Oncology: Padcev Is Building The Market It Wants
- Wedbush Reiterates Outperform on Aktis Oncology, Maintains $35 Price Target
- Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519
- Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3
- Aktis Oncology, Inc. (AKTS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- Oppenheimer Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $40
- Wedbush Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $35
- BMO Capital Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $37
- Bank of America Sees Bargains in These 16 Knocked-Down AI Stocks
- Micron and 15 Other Stocks To Play The AI Buildout Race: They Are Still 20% Below Highs
Your note
Sign in to keep a note on AKTS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CZIBERE AKOS M.D. | Officer | Sale | Sep 22, 2026 | 0 |
| ECOR1 CAPITAL, L.L.C. | Unknown | Purchase | Jan 11, 2026 | 0 |
| FOLEY TODD | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Jan 11, 2026 | 0 |
| GADICKE ANSBERT S. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jan 11, 2026 | 0 |
| HERRMANN KEN M.D. | Director | Sale | Jul 19, 2026 | 0 |
| KIM HELEN SUSAN | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Jan 11, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| MPM Bioimpact LLC | 9.00% | 4,835,872 | 87.77M | Jun 29, 2026 |
| EcoR1 Capital, LLC | 8.98% | 4,824,469 | 87.56M | Jun 29, 2026 |
| Blue Owl Capital Holdings LP | 5.71% | 3,070,219 | 55.72M | Jun 29, 2026 |
| Blackrock Inc. | 4.24% | 2,278,358 | 41.35M | Jun 29, 2026 |
| T. Rowe Price Investment Management, Inc. | 3.82% | 2,051,447 | 37.23M | Jun 29, 2026 |
| Wellington Management Group, LLP | 3.66% | 1,966,244 | 35.69M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 2.72% | 1,462,244 | 26.54M | Jul 30, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 1.26% | 676,577 | 12.28M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.09% | 585,135 | 10.62M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.01% | 542,593 | 9.85M | Aug 30, 2026 |
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 0.94% | 507,000 | 9.20M | Jun 29, 2026 |
| T. Rowe Price Eqy. Fd.s, Inc.-T. Rowe Price Inst. Small-Cap Stock Fd. | 0.67% | 358,947 | 6.51M | Jun 29, 2026 |